Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• Autori principali: Qiao Liu (Autore), Zhen Zhou (Autore), Xia Luo (Autore), Lidan Yi (Autore), Liubao Peng (Autore), Xiaomin Wan (Autore), Chongqing Tan (Autore), Xiaohui Zeng (Autore)
• Natura: Libro
• Pubblicazione: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...